



City Research Online

City, University of London Institutional Repository

Citation: Dipper, L., Devane, N., Barnard, R., Botting, N., Boyle, M., Cockayne, L., Hersh, D., Magdalani, C., Marshall, J., Swinburn, K. & et al (2024). A feasibility randomised waitlist-controlled trial of a personalised multi-level language treatment for people with aphasia: The remote LUNA study. PLOS ONE, 19(6), e0304385. doi: 10.1371/journal.pone.0304385

This is the accepted version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/33143/>

Link to published version: <https://doi.org/10.1371/journal.pone.0304385>

Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

City Research Online:

<http://openaccess.city.ac.uk/>

publications@city.ac.uk

A feasibility randomised waitlist-controlled trial of a personalised multi-level language treatment for people with aphasia: the remote LUNA study

Lucy Dipper^{1*}¶, Niamh Devane^{1&}, Rachel Barnard⁴, Nikki Botting^{1&}, Mary Boyle², Lin
Cockayne¹, Deborah Hersh³, Carla Magdalani¹, Jane Marshall^{1&}, Kate Swinburn¹, Madeline
Cruice^{1¶}

¹ Department of Language and Communication Science, School of Health and Psychological
Sciences, City, University of London, UK

² Montclair State University, Montclair, New Jersey, USA

³ Curtin School of Allied Health and EnAble Institute, Curtin University, Perth, Australia

⁴ Wolfson Institute of Population Health, Queen Mary University of London, UK

¶* Corresponding author

[Email:l.t.dipper@city.ac.uk](mailto:l.t.dipper@city.ac.uk)

¶ LD and MC are joint senior authors

& These authors contributed equally to this work

22 **Abstract**

23 Background

24 Stroke survivors with aphasia want to improve their everyday talking (discourse). In current
25 UK practice, 90% of speech and language therapists believe discourse assessment and
26 treatment is part of their role but are hampered by barriers in resources, time and
27 expertise. There is a clinical need for well-articulated discourse assessment and treatments.
28 LUNA is a multi-level treatment targeting words, sentences and discourse macrostructure in
29 personal stories that addresses this clinical need.

30 Objectives

31 This study aimed to assess the feasibility and acceptability of LUNA trial procedures in a
32 randomised waitlist-controlled trial; and to evaluate preliminary efficacy.

33 Methods

34 This paper reports a phase II, waitlist-controlled, proof-of-concept feasibility trial.
35 Participants with chronic aphasia (n=28) were recruited from the community and
36 randomised to an Immediate (n=14) or Delayed (n=14) group. LUNA treatment was
37 delivered twice weekly for 10 weeks via the videoconferencing technology, Zoom. Feasibility
38 was assessed in terms of participant recruitment and retention, adherence, missing data,
39 and treatment fidelity. Preliminary treatment efficacy was assessed in terms of between
40 group differences in outcome measures relating to discourse, language, and psychosocial
41 state.

42 Results

43 The remote LUNA trial was feasible: 85% of those eligible consented to the trial; trial
44 retention was 86%; 87% of treatment sessions were delivered as scheduled, and 79% of

participants completed 80%+ of the treatment programme; data was missing only for participants who withdrew; treatment fidelity was high at 92% adherence; and only one clinical outcome measure demonstrated ceiling effects. ANCOVA analysis of the clinical outcome measures revealed group differences with medium and large effect sizes, indicating, improvements in the production of words, sentences, discourse macrostructure, overall language functioning (WAB-R), and psychosocial state (VAMS) following LUNA treatment. For most outcomes measured, similar treatment benefits were suggested in a secondary, non-parametric analysis.

Conclusions

Large-scale evaluation of the clinical efficacy and cost-effectiveness of LUNA is warranted and supported by these findings.

Clinical trials registration: NCT05847023 (clinicaltrials.gov)

Introduction

Stroke is a leading cause of long-term disability worldwide (1), and approximately a quarter of stroke survivors will experience chronic aphasia (2), a condition where communication is impacted with far-reaching consequences (3). Aphasia affects the person's abilities in speaking, listening, reading and writing, and has a negative impact on family and family roles, friendships, work, and access to healthcare and community life (4). People with aphasia specifically want to improve their everyday talking - which is also referred to as 'connected speech' or 'discourse' - in their rehabilitation with speech and language therapists (5). Discourse is defined as a unit of language bigger than a sentence (6); it is complex and requires processing multiple levels of language, including word retrieval, sentence construction, and adherence to an overarching discourse macrostructure.

Discourse also has a key role in conversation (7). For these reasons, discourse assessment has been identified as an ideal measure of functional communication in speech and language therapy (SLT) trials (8); and improved discourse is a prioritised outcome for people living with aphasia (5).

The use of discourse assessment and treatment is gaining research interest and is now recommended in best practice guidelines (9). However, conceptual and methodological issues remain (10). There is a lack of consensus on how to define and assess discourse in the SLT field. SLTs surveyed across five countries defined discourse analysis differently (11). International effort to establish a core outcome measure of functional communication for aphasia rehabilitation research did not initially reach a consensus (12), and more than 500 different measures of discourse have been identified in reviews (10, 13, 14). Although the majority of SLTs believe discourse analysis is part of their professional role (15), there are practical barriers in assessing discourse that limit use in clinical practice. For example, a survey of UK SLT practice (n=211) revealed that although 30% of SLTs collected discourse samples, only 5% of SLTs regularly transcribed them, and SLTs lacked relevant training and skills in interpreting discourse assessment findings (15). Transcription is important because it allows for detailed analysis and subsequent relevant clinical management. It is especially important for personal narratives where the content of the discourse cannot be predicted. Despite its central role in everyday talk, the transcription, analysis and treatment of discourse is not widespread in UK NHS SLTs' routine practices. There is a clinical need for well-articulated discourse assessments and treatments that are straightforward for clinicians to use.

While there is an evidence base for word and sentence treatments (16, 17), the evidence base for discourse treatments is only emerging with a recent systematic review (13) synthesizing 25 studies reporting on 127 participants and categorising discourse treatments into 5 different types. Although there was a wide range of different beneficial outcomes across these diverse treatments (including improved words, sentences and discourse macrostructure), the three studies showing most promise for improving multiple aspects of discourse reported a multi-level approach to treatment (18-20).

LUNA treatment

This paper describes a novel discourse treatment for aphasia called, Language Underpins Narrative in Aphasia (LUNA). LUNA is a manualised, theory-based (21), codesigned (22) multi-level discourse intervention, which aims to facilitate the telling of personal stories through word, utterance (sentence) and discourse macrostructure level activities. It integrates familiar treatments - semantic feature analysis, mapping therapy, story grammar - to provide flexible metalinguistic tools for improving people's confidence and ability to express themselves through narrative. These treatment activities are integrated through the use of a personally chosen story on which to work during treatment. LUNA is distinct from previous multi-level treatments in its form of personalisation (the focus on a story that the person has selected and wants to tell to family and friends); its explicit focus on meta-linguistic awareness (activities are aimed understanding the person's own language profile); and meta-cognitive awareness to support self-management.

LUNA is personalised in two ways. Firstly, there is personalisation in the subject material.

Participants choose stories from their own lives that they want to share with others.

Secondly, there is personalisation in the linguistic content. The participant chooses the words, sentences, and macrostructure they use to tell their story in collaboration with the therapist during treatment. There is evidence that therapy outcomes are enhanced when personalised content is included (23), and that this stimulates neural re-organisation (24). In addition, the treatment of personal stories can have broader effects. The sharing of stories may help people to express themselves, and to interact and share more with family and friends (25-27). LUNA is a meta-cognitive (28) and meta-linguistic (29) therapy, encouraging participants to reflect on their own thinking and language; to learn about the nature of language, and the detail of their own linguistic skills and impairments; and to practise using the new skills in everyday contexts. Ultimately, this means the use of personal stories may serve to increase motivation to engage with and complete the treatment programme - of relevance to discussions of feasibility and adherence described later in the paper.

LUNA was initially devised for face-to-face delivery. However, this study coincided with the 2020 COVID-19 pandemic. All assessment and treatment procedures were therefore adapted for remote delivery using videoconferencing technology, specifically Zoom. Research has demonstrated that people with aphasia can comply with remote assessment and treatment and find such procedures acceptable (30) and that remote treatment can have positive outcomes (31-33). Remote delivery of multi-level discourse treatment for aphasia has not previously been trialled.

This proof-of-concept study comprised a phase II randomised controlled trial, comparing remote LUNA treatment with a waitlist control. It aimed to test the feasibility of trial

procedures and explore indicative outcomes from LUNA treatment. Specifically, this study aimed to:

1. Test the feasibility of a definitive trial comparing remote LUNA with a waitlist control, using the following feasibility endpoints: a) participant recruitment and retention rates; b) adherence to treatment sessions; c) counts of missing data; and d) fidelity scores for treatment delivery.
2. Explore the appropriateness of the trial outcome measures, as indicated by the level of variability of scores, missing data, and floor and ceiling effects.
3. Investigate preliminary efficacy by comparing outcomes on discourse, language, and measures of psychosocial state across participants who have and have not received the LUNA intervention.

Materials and Methods

Trial Design

The study was a single-blind, waitlist, randomised, controlled, phase II, proof-of-concept, feasibility and acceptability trial of remote LUNA for people with chronic post-stroke aphasia.

This study was granted ethical approval by the City, University of London, School of Health Sciences Research Ethics Committee (ETH1920-0210) in February 2020; similarly, approval was granted in June 2020 for amendments (ETH1920-1651) following the COVID-19 national lockdowns, prior to the trial starting recruitment. The trial sponsor was City, University of

London, and the study is funded by the Stroke Association (TSA2017/01). The funder approved the adapted study on 20.05.2020.

Participants

Twenty-eight participants were recruited to the remote LUNA study between 16/06/2020 and 06/08/2020. Twenty-eight was an intentional over-recruitment on a target of at least 24 participants, to mitigate for possible attrition. The intention was to ensure a sample size of 24 (12 treated, 12 control) following recommendations for feasibility trial sample sizes (34, 35). Inclusion criteria were adults (18+ years); diagnosis of ischaemic or haemorrhagic stroke; and aphasia due to a stroke that occurred at least 12 months prior to recruitment. Additionally, participants were literate and fluent users of English prior to their stroke (self-reported), with adequate hearing and vision with aids or glasses (for example to see pictorial and written assessment and treatment materials). Participants were required to have access to a computer or tablet and an internet connection. They needed to be able to download and access Zoom, either independently or with the support of a friend/neighbour/family member.

Participants were excluded if they were receiving speech and language therapy elsewhere or participating in any other aphasia treatment research project for the duration of the study. Usual stroke supports, such as voluntary sector support groups, could proceed. Although many of these support services were curtailed due to COVID-19, some moved online. Participants with severe aphasia, as defined as a score of 7 or less on the Frenchay Aphasia Screening Test (FAST) (36), were excluded. This criterion was applied because remote LUNA was designed for people with some verbal output. It was also judged that

people with severe aphasia would struggle to manage remote delivery. Participants were also excluded if they had a secondary cognitive diagnosis such as dementia. This was established via self-report and/or the confirmation of the referring group co-ordinator and/or by expert clinical judgment of research project staff. Screening and recruitment were completed by experienced SLT members of the research team (authors KS and MC).

Participants were a volunteer sample recruited by advertising the study through UK-based stroke support groups, signposting people to the dedicated project website or self-referral. Self-referrals were accepted from anywhere in the United Kingdom. All recruitment, assessment, treatment, and interview sessions were conducted online using Zoom. All participants gave written consent. All participant information sheets and consent forms were made accessible to people with aphasia following evidence-based recommendations (37). Recruitment began on 16 June 2020 (first screening) and data collection finished on 28 April 2021 (final assessment).

Intervention

The LUNA treatment is specified in the TIDIER checklist (see S1 Checklist). Before treatment started, participants were supported to choose two personal narrative monologues to share. They were given about a week to consider their choice and then both narratives were elicited at the beginning of the first assessment session, under controlled conditions, following a set procedure. Participants then decided which of the two narratives they wished to work on in treatment sessions. This choice was shared with therapists, and the chosen narrative was transcribed, analysed and deconstructed to identify potential treatment targets, ahead of the first treatment session.

210

211 Remote LUNA comprised 20 hours of treatment, 2 sessions per week of 60 minutes each, for
212 10 weeks. A set-up week preceded treatment, where the SLT and participant met for an
213 hour to agree on goals – the deconstructed narrative was used as a basis for this discussion.
214 This resulted in an intervention lasting 11 weeks, consisting of 21 hours of treatment in
215 total. In week 2-11, the chosen personal narrative was progressively re-built through
216 integrated word, phrase, clause, multi-clause, and discourse macrostructure treatment
217 activities. Treatment targeted three language levels: word (wks 1-4); utterance (weeks 5-7);
218 and macrostructure (weeks 8-10).

219

220 All sessions were delivered over Zoom. One session per week was delivered by a qualified
221 SLT and the other session was delivered by an assistant: a student SLT (SSLT). Both the SLT
222 and SSLT followed the treatment manual and received guidance via remote supervision.
223 Linked ‘challenge tasks’ promoted generalisation outside of treatment sessions.

224

225 A team of three experienced SLTs and twelve SSLTs delivered remote LUNA to the 28
226 participants. Alongside guidance from the treatment manual, SLTs received six days of
227 remote training across a three-week period prior to implementing treatment, in addition to
228 weekly remote group supervision from a clinical linguist (author LD) throughout the trial.
229 SSLTs received fourteen hours of remote training and received a mixture of 1:1, paired and
230 group supervisions remotely throughout the trial. Each participant worked with the same
231 SLT and SSLT for treatment for the duration of the study (there were different screening and
232 Assessor SLTs for recruitment and assessment – see below) .

233

234 Feasibility outcomes

235 Feasibility of remote LUNA was tested in terms of participant recruitment and retention,
236 adherence throughout the study, and missing data. To inform a future trial, treatment
237 fidelity, appropriateness of outcome measures and estimated sample size were also
238 explored. Six feasibility endpoints were outlined:

239

- 240 a) Feasibility of recruitment and retention to the trial: Data comprised of counts/
241 proportion of those who expressed interest, were screened and deemed eligible,
242 those who consented, attrition and reasons for attrition if known.
- 243 b) Adherence: data comprised of number/proportion of treatment sessions attended as
244 scheduled, and percentage completion of the LUNA treatment programme; reasons
245 for non-attendance.
- 246 c) Missing Data: Data comprised of attrition rates and counts of other missing data.
- 247 d) Assessment of treatment fidelity through ratings of provider adherence to the LUNA
248 manual/essential elements; reliability of the rating procedure was checked and
249 whether scores were affected by the treatment provider, treatment level or group
250 allocation.
- 251 e) Appropriateness of outcome measures: indicated by the level of variability of scores,
252 missing data, and floor and ceiling effects.
- 253 f) Estimate of sample size for a future trial: based on a preliminary power calculation
254 using WAB-R effect sizes.

255

Treatment Fidelity

Remote LUNA yielded a total of 560 hours of Zoom-recorded treatment sessions (28 participants x 20 sessions), and a sample of 10% of sessions (56hrs) was selected for review. Sample selection was stratified (by authors LD and MC)— it was organised to ensure that a range of providers and treatment levels were sampled but was otherwise random (i.e. done without reference to session content or participant details). Treatment fidelity (TF) was assessed by evaluating providers' adherence to the treatment manual (as determined by SLT student raters) using a TF checklist of essential elements of LUNA.

The checklist was developed iteratively with the research team, co-designers with aphasia, co-designer SLTs, LUNA therapists, and research students. The final checklist (Table 1) comprised 12 items. These were used by all treatment providers, during the treatment phase, as a self-reflective tool after completing sessions. The same checklist was then used post-treatment phase by SLT student raters to evaluate providers' adherence to the treatment manual. Two of these students were not part of the team that delivered intervention, and two were. The latter two students did not evaluate their own sessions and so all four students were considered unbiased raters.

Table 1: LUNA treatment fidelity checklist items

Item	Description*
1	The SLT/SSLT promotes partnership and collaboration
2	Clear goals orientation in the session
3	Client is actively involved in making decisions in the session

- 4 Emphasis on the client's understanding (meta-awareness)
- 5 Evidence of personalisation
- 6 Good therapeutic practice
- 7 Session relates to 1 of the 3 LUNA levels (word, sentence, discourse)
- 8 Both story and non-story treatment targets are used in the session
- 9 Flexibility and/or responsiveness is evident in the session
- 10 Evidence of supportive performance monitoring i.e., feedback and reflecting on progress
- 11 Work in the session is explicitly linked to the challenge tasks
- 12 Evidence that the manual is being followed

*Definitions and examples of each item that appear in the full checklist have been omitted here for brevity.

In the post-treatment phase, SLT student raters evaluated fidelity by marking each of the 12 items as either present or absent (38) including additional qualitative notes to justify their decisions. Fifty-six hours (10%) of treatment sessions were viewed by four research students. These raters received training (4 hours) which comprised group and independent viewing and discussion, and independent benchmarking. Training was carried out on six representative sessions, selected to include: word, sentence, discourse macrostructure treatment activities; and delivery by SLTs and SSLTs. Percent agreement on benchmarked sessions was 72% (26/36 items) with most discrepancies on items 8, 10 and 11. These were discussed, with refinements added to the checklist.

Fourteen sessions were allocated to each of the four raters (total 56 sessions) and assessed independently. Eight (8) of 56 sessions were subjected to intra-rater reliability checks with

ratings separated by a period of at least 1 month, and a further eight (8) of 56 sessions subjected to inter-rater reliability checks. Reliability was determined by calculating percentage agreement with agreement interpreted as high if >70% (39).

Clinical outcome measures

Participants completed assessments at three time points: T1 (weeks 1 & 2), T2 (weeks 13 & 14) and T3 (weeks 25 & 26). Only efficacy outcomes at T2 are reported here, to enable a comparison of treated (i.e. Immediate treatment group) and untreated (i.e. Delayed treatment group) participants. Participants in the Immediate group received LUNA treatment between T1 and T2. Participants in the Delayed group received treatment between T2 and T3, but their efficacy results are not reported in this paper. Participants were recruited to the study in two waves to allow for appropriate staffing.

Feasibility findings from all three timepoints are presented for completeness. For the preliminary efficacy evaluation, we report clinical outcomes from T1 and T2 only, comparing the experimental (Immediate) group who had received treatment at this point to the control (Delayed) group who had not yet received treatment.

At each timepoint, assessment was completed by LUNA Assessors (n=2) who were qualified SLTs who were kept blinded to participant treatment group allocation throughout the study. Assessment processes were adapted for online delivery and manualised. Assessors undertook this development work across a 6-week period prior to assessing participants, also using this time to undertake training and practice remote assessment with 3 people with aphasia who were part of the LUNA PPI Advisory group. For the discourse analysis,

Assessors were given weekly training over a two-month period (including training with a clinical linguist and self-directed exercises). In addition, they received regular supervision from an SLT (author MC) during the assessment phases and from a clinical linguist (author LD) during the narrative assessment phase.

Personal narratives measure (LUNA Discourse Protocol)

Participants produced two personal narratives at each assessment point, which were recorded, transcribed, and analysed by according to the LUNA Research Discourse Analysis Protocol. Several discourse metrics were calculated from the analysis (see S2 Appendix), with the selection made during codesign session with the SLTs and guided by: use of a measure in the systematic review (13), the psychometric properties (40, 41) of the measures, and the appropriateness of the measure for measuring change after LUNA treatment. A novel measure ‘narrative words’ was designed by the research team which, while similar to Correct Information Units (CIUs), was intended to be more clinically feasible as an analysis. Number of narrative words was proposed as the primary clinical outcome measures. Other discourse metrics included: number of CIUs, percentage of CIUs, and number of CIUs/minute (following the protocol of Nicholas and Brookshire, 1993); number of narrative words, percentage of narrative words, and number of narrative words/minute; number of complete utterances and percentage of complete utterances; number of multiclaue utterances and percentage of multi-clause utterances; predicate argument structure (PAS) score; a Story Grammar score; and a count of the number of clear reference chains (see S2 Appendix).

335

336 The Western Aphasia Battery-Revised (WAB-R) (42)

337 The WAB-R is a performance-based outcome measure assessing speaking, auditory
338 comprehension, naming, and repetition across four sections. It classifies aphasia type and
339 generates an aphasia severity score between 0-100, the Aphasia Quotient (AQ), where a
340 score of 0-25 is very severe, 26-50 is severe, 51-75 is moderate, 76+ is mild. A cut-off score
341 93.8 and above is considered "normal or nonaphasic" (pg. 91, 42). The AQ score was used in
342 the analysis. It was standardised on people with aphasia (n=150) and controls (n=59) (43).
343 Internal consistency and interrater reliability are good (44). It is internationally used as part
344 of the core outcome set for aphasia trials (12) and has been validated for remote online
345 delivery (45).

346

347 The Communicative Participation Item Bank (CPIB) – General Short Form (46)

348 The CPIB is a 10-item patient-reported outcome measure (PROM). Patients rate the level of
349 interference caused by their condition for each item, on a 4-point scale. Items ask, for
350 example, how much the condition interferes with communicating with people known to the
351 person with aphasia, with people not known to them, when giving someone detailed
352 information, and when communicating as part of a small group. Scores are converted to a
353 summary score which ranges between 0-30 where a high score is favourable, representing
354 little interference from the health condition. The summary score was used in the analysis.
355 The measure was designed for community-dwelling adults with spasmodic dysphonia but
356 was adapted for aphasia with a representative sample. The short form is appropriate and
357 valid for people with aphasia (47).

358

The Communication Confidence Rating Scale for Aphasia (CCRSA) (48, 49)

The CCRSA is a 10-item PROM. Patients rate their confidence in communicating in different contexts on a scale of 0-100. Scores are converted to derive a total score of between 10-40, where 40 represents feeling very confident in communicating. The total was used in the analysis. It is the only communication confidence measure in the field and is increasingly used in treatment studies. It was validated on 47 people with aphasia from different treatment settings. The psychometric properties of sensitivity to change and reliability (inter- and intra-) remain to be established (49).

The Assessment for Living with Aphasia (ALA) (50)

The ALA is a 45-item pictographic PROM assessing aphasia-related quality of life and was developed by an internationally leading aphasia charity in Canada. Questions cover four domains relating to living with aphasia (language impairment, participation, personal factors, and environmental factors) and there is a summary question relating to the overall impact of aphasia. The total scores of these 5 items are divided by 37 to create a single mean score. The mean score ranges between 0-4, where 4 represents a perception of good quality of life. The mean score was used in the analysis. Acceptable construct validity and reliability have been established (51).

Visual Analogue Mood Scales (VAMS) – Sad (52)

Following feedback from LUNA advisors with aphasia (and supported by the research team), a single item mood measure, the Visual Analogue Mood Scales (VAMS) Sad scale was added to all testing time points. Scores range between 0-100, with 100 representing a maximal level of sadness and zero representing a minimal level (or absence) of that mood. It has

been used successfully in aphasia studies (53, 54) and takes three minutes to complete. It is accessible and appropriate to be used with stroke survivors who have aphasia (55). Content validity (52, 56) and test re-test reliability (57) have been established.

Randomisation

Stratified random sampling was used. After T1, participants were classified into two groups: group (i) 'mild' and group (ii) 'moderate' aphasia severity based on WAB AQ score. Randomisation was carried out by a research team member (author NB) who was blinded to severity by use of the group labels (i) and (ii), and who was also blinded to screening and assessment results and had no knowledge of the participants. Participants were randomised to the immediate or delayed condition by the following method: for each group (i/ii, i.e. mild/moderate), participant numbers were written on identical pieces of paper which were then folded in half; these were placed in a box and shaken, then pulled out in a random order; in alternating fashion, each number was allocated to the Immediate group or the Delayed group.

Blinding

Limited members of the research team were aware of participant treatment group allocation (Immediate/Delayed). These members were the joint principal investigators, project manager, treating SLTs and SSLTs, and the qualitative researcher. Other members of the research team (n= 6) were kept blinded to group allocation. This included, most importantly, the Assessors (n=2) who were qualified SLTs kept blinded to group allocation throughout the study – this included them agreeing to delete their social media accounts for the duration of the trial in order to remove the risk of unblinding in that context.

Recruitment sessions were organised by the project manager and one principal investigator, and assessors had no access to participant files or details that would reveal group allocation. Remote working, imposed by COVID-19, also ensured that assessors had minimal contact with the unblinded members of the research team, beyond formal supervision with the Principal Investigators. Participants were instructed not to reveal their group allocation to assessors during assessment sessions. A log was kept of any instances of unblinding and near misses, with the reason for the unblinding.

Analyses

Regarding feasibility, analyses were descriptive to ascertain feasibility endpoints such as recruitment and attrition. Adherence, in terms of sessions delivered as scheduled and participants' completion of the treatment programme, was recorded as a percentage of sessions. With respect to treatment fidelity, a score was calculated for each item as a percentage of items marked as present and interpreted as high if 80-100% and low if 50% or lower (scores 51%-79% being medium) (58). Fidelity findings were also examined in relation to treatment provider (SLT/SSLT), treatment level (word, sentence, discourse) and group (immediate, delayed).

Regarding clinical outcomes, a between-group comparison analysis was carried out . ANCOVA compared assessment scores of both groups at T2 (when the Immediate group had received treatment, but the Delayed group had not) in measures of discourse, language, and psychosocial state, using T1 scores as a covariate. These analyses were exploratory, examining whether the treatment showed promise of efficacy. An indication of treatment promise would be seen in a significant group effect favouring the immediate condition

and/or effect size (partial eta squared: $\eta^2 \sim 0.01$ = small effect; $\eta^2 \sim 0.06$ = medium effect; $\eta^2 \sim 0.14$ = large effect). Preliminary power calculations were conducted based on the effect sizes of the standardised language measure (WAB-R) to determine sample size for a future clinical efficacy trial of LUNA.

Results and Discussion

Participants

Twenty-eight (28) people with aphasia were recruited to the trial in a two-month period between 16 June 2020 and 6 August 2020. Fifty-eight (58) people expressed an interest, 40 people were screened using the FAST, and 28 were randomised (Figure 1).

[Figure 1 inserted here]

Participants were on average ~60 years old, ranging from 34-83 years (See Table 2). They were predominantly from a White British ethnic group, university educated, and had held highly skilled positions in their working lives as measured by the Standard Occupational Classification (59). All participants had English as their primary language with more than half the sample using more than one language but only three participants described an advanced ability in other languages . Participants came from two of the four UK countries and from seven of the nine regions in England, representing a large geographical spread. There were no participants from Wales and Northern Ireland, or from the West Midlands or the North East of England. See Table 2 for participant characteristics. Participants were on average 55 months post-stroke (range 14-181 months) and largely balanced between mild and moderate aphasia severity.

454 **Table 2: Participant characteristics at baseline (T1)**

		Immediate (n=14)	Delayed (n=14)	Total (n=28)
Age		57.72 years	58.07 years	59.82 years
	(range)	(41-83)	(34-82)	(34-83)
Ethnicity				
	White British	13 (93%)	13 (93%)	26 (93%)
	White other	1 (7%)	1 (7%)	2 (7%)
Language				
	Mono-lingual	14 (100%)	11 (79%)	25 (89%)
	Multilingual	0	3 (21%)	3 (11%)
Education				
	Secondary	5 (36%)	5 (36%)	10 (36%)
	Further	2 (14%)	0	2 (7%)
	Higher	7 (50%)	9 (64%)	16 (57%)
Occupation				
	1.Manager/Director	2 (14%)	6 (43%)	8 (29%)
	2.Professional	3 (21%)	2 (14%)	5 (18%)
	3.Associate Professional	3 (21%)	1 (7%)	4 (14%)
	4.Administrative and secretarial	3 (21%)	3 (21%)	6 (21%)
	5.Skilled trade	1 (7%)	0	1 (4%)
	6.Caring and leisure	0	0	0
	7.Sales and customer service	0	0	0
	8.Machine operatives	1 (7%)	1 (7%)	2 (7%)
	9.Elementary	0	0	0
	(Retired)	1 (7%)	1 (7%)	2 (7%)
Geographical Region				
	South East	5 (36%)	2 (14%)	7 (25%)
	South West	5 (36%)	2 (14%)	7 (25%)

London	2 (14%)	3 (21%)	5 (18%)
East of England	0	3 (21%)	3 (11%)
Scotland	2 (14%)	1 (7%)	3 (11%)
East Midlands	0	1 (7%)	1 (4%)
North West	0	1 (7%)	1 (4%)
Yorkshire and the Humber	0	1 (7%)	1 (4%)
Living status			
Alone	4 (29%)	3 (21%)	7 (25%)
With partner and family	8 (57%)	9 (64%)	17 (61%)
With other family	2 (14%)	2 (14%)	4 (14%)
Stroke/handedness information			
Right handedness	8 (57%)	14 (100%)	22 (79%)
Left handedness	5 (36%)	0	5 (18%)
Ambidextrous	1 (7%)	0	1 (4%)
Right hemiplegia	9 (64%)	12 (86%)	21 (75%)
Left hemiplegia	1 (7%)	0	1 (4%)
No hemiplegia	4 (29%)	2 (14%)	6 (21%)
Mean time post stroke in months	59	55	55
(range)	(14-181)	(20-105)	(14-181)
History of stroke			
Single stroke event	12 (86%)	12 (86%)	24 (86%)
History of 2 strokes	1 (7%)	2 (14%)	3 (11%)
History of >2 strokes	1 (7%)	0	1 (4%)
Aphasia severity			
Not aphasic by WAB-R score**	2 (14%)	0	2 (7%)
Mild (76-94 WAB AQ)	6 (43%)	6 (43%)	12 (43%)
Moderate (51-75 WAB AQ)	6 (43%)	7 (50%)	13 (46%)
Severe (26-50 WAB AQ)	0	1 (7%)*	1 (4%)

Aphasia Classification†

Broca's	2 (14%)	2 (14%)	4 (14%)
Wernicke's	2 (14%)	1 (7%)	3 (11%)
Conduction	5 (36%)	6 (43%)	11 (39%)
Anomic	3 (21%)	5 (36%)	8 (29%)
Not aphasic by WAB score**	2 (14%)	0	2 (7%)

Multilingual = participants who describe advanced or native ability in another language. WAB-R AQ = Western Aphasia Battery-Revised Edition, Aphasia Quotient score. *The FAST was used at screening to screen out participants with severe aphasia, but at baseline testing one participant was classified within the severe range on the WAB-R. ** Although an AQ of 93.8 or above is suggested as a cut-off for aphasia diagnosis, we included participants who scored in the range 93-100 on the WAB-R because recent studies have shown people with such scores perform significantly differently to controls in discourse tasks. † Aphasia classifications not represented in this sample: global; isolation; transcortical motor; transcortical sensory

Feasibility outcomes

a) Participant recruitment and retention

The remote LUNA study recruited 28 participants, which was 100% (28/28) of the target sample size. In brief, 48% (28/58) of those who expressed an interest, and 85% (28/33) of those who were eligible consented to participate in the trial (Table 3). See Figure 1 for further detail about reasons for exclusion at each stage. Four participants withdrew from the study due to ill health: three from the Immediate group following T2 testing, and one from the Delayed group after treatment but before T3 testing. Therefore, retention was 86% (24/28).

Figure 1. Participant flow diagram

{insert Figure 1 here}

Table 3: Participant recruitment and retention

	Proportion or Rate	Number
Proportion eligible of those identified	48%	28/58
Proportion eligible of those screened	83%	33/40
Proportion consented of those eligible	85%	28/33
Rate of eligible/month	14/month	28 (recruited in total in 2 months)
Proportion of withdrawals		
Overall:	14%	4/28
By group:		
- Immediate	11%	3/28
- Delayed	4%	1/28

b) Adherence

Eighty-eight percent (88%) of *assessment* sessions were attended as scheduled, i.e., at the time and date arranged, and for the scheduled length of time. The remaining 12% either needed an additional session in order to complete the intended assessment or needed a session to be rescheduled. Reasons for 12% not going ahead as planned included technical issues (in the majority of cases) and health or personal reasons.

Participants attended 87% of remote *treatment* sessions as scheduled. Reasons for 13% sessions not going ahead as planned were: the session was split across more than one session on the same day due to technical difficulties (31%); the session started late due to technological (29%) or other reasons (13%); ill health (10%); or was rearranged for a different day (17%). In terms of completion of the LUNA treatment programme, 54%

participants (n=15/28) attended 90-100% of the programme, 25% of the participants (n=7) attended 80-89% of the programme, and 21% of participants (n=6) attended 67-79% of the programme.

There were minimal differences between the Immediate and Delayed groups in terms of adherence, indicating that having to wait for treatment was not a significant factor.

c) Missing data

All (28/28) participants completed assessment sessions at T1 (baseline) and T2 (post-treatment for the Immediate group); and 86% (24/28) completed assessment sessions at T3, with four participants withdrawing due to ill health prior to T3. Completeness of data was also monitored at the item level, and data was either all present for assessments, or all missing (i.e. for those four participants at T3).

d) Treatment fidelity

The remote LUNA treatment was delivered as intended, with high adherence to the manual. 92% of items were marked as present (616/672). Half the checklist items had 100% adherence (items 1, 4, 5, 6, 7, 9), five items had >80% (items 2, 3, 10, 11, 12) and only one item on the checklist, item 8, had low adherence at 32%. This data is underpinned by 100% intra-rater reliability findings, and 98% inter-rater reliability findings. Treatment adherence was explored in more detail in relation to provider, treatment level, and group. Only 8% (56/672) of items were marked as absent. SSLT sessions had more items rated absent (63%, 35/56) than SLT sessions (38%, 21/56). Discourse level sessions had more items rated absent (43%, 24/56) than word (29%, 16/56) or sentence (29%, 16/56) sessions. There were more

items rated as absent in the Immediate group (55%, 31/56) compared to the Delayed group (45%, 25/56).

e) Appropriateness of trial outcome measures

The outcome measures data was appropriate and usable. There was a change in mean scores over time in the expected direction, suggesting sensitivity to the effects of the treatment. No floor or ceiling effects were observed except for the VAMS-Sad where, at T1, T2, and T3, 17.9%, 42.9%, and 17.9% of participants scored the highest score possible (0; reflecting absence of sadness). There was no missing data due to participants not being able to complete measures, only from participant withdrawals.

Regarding unblinding, assessors were inadvertently unblinded for seven (7) of the 28 participants. For example, on one occasion a participant screenshared their calendar with an Assessor to find an assessment, inadvertently making treatment sessions appointments visible. On another occasion, the Assessor rather than SLT, SSLT or Project Manager was called for technological support when someone couldn't access zoom for the treatment session.

Clinical outcomes

Clinical outcomes were measures of discourse from personal narratives. Descriptive statistics are presented for the discourse measures in Table 4 and for the measures of language and psychological state in Table 5. At T1 (pre-treatment) there were no significant differences between groups (all p values > 0.3).

537 **Table 4: Means and standard deviations for discourse measures**

	T1		T2	
	mean (SD)		mean (SD)	
	Immediate	Delayed	Immediate	Delayed
Narrative words:				
number	428.1 (403.1)	450.8 (490.3)	599.3 (388.1)	494.5 (543.8)
percentage	66.5 (10.2)	65.3 (14.4)	69.5 (13.5)	66.1 (14.2)
number per minute	41.96 (21.36)	49.52 (29.27)	45.44 (21.54)	58.27 (30.03)
Correct Information Units:				
number	372.4 (369.1)	399.4 (440.0)	532.0 (365.9)	435.8 (489.5)
percentage	61.1 (11.2)	62.1 (13.9)	64.2 (13.5)	62.7 (13.3)
number per minute	35.87 (20.06)	43.60 (27.09)	40.03 (20.68)	50.49 (27.33)
Utterances:				
number complete	38.9 (37.1)	35.0 (40.0)	54.6 (38.7)	38.6 (45.0)
% complete	59.0 (21.8)	54.1 (26.7)	66.9 (22.7)	51.1 (28.9)
number multiclause	13.9 (15.8)	18.0 (23.0)	22.1 (18.7)	21.1 (27.6)
% multiclause	20.7 (15.5)	25.2 (16.6)	27.6 (18.6)	24.6 (21.4)
Predicate Argument Structure	1.8 (0.2)	1.7 (0.3)	1.8 (0.2)	1.7 (0.2)
Story Grammar:				
number of elements	3.6 (1.6)	4.0 (2.0)	4.1 (1.2)	4.0 (2.0)

Clear reference chains:				
number of chains	8.9 (9.9)	7.1 (7.5)	13.7 (11.7)	7.9 (9.6)

nb: italics indicate *skewed data*.

Table 5: Means and standard deviations for measures of language and psychological state

Scale [score range]	T1		T2	
	mean (SD)		mean (SD)	
	Immediate	Delayed	Immediate	Delayed
WAB-R AQ [0-100]	76.44 (13.56)	73.20 (13.54)	77.86 (12.01)	72.47 (13.39)
CPIB [0-30]	13.14 (3.92)	10.07 (4.10)	13.71 (4.01)	12.00 (5.46)
CCRSA [10-40]	28.79 (5.54)	27.14 (4.22)	29.64 (3.95)	27.50 (4.47)
ALA [0-4]	2.66 (.54)	2.42 (.46)	2.79 (.55)	2.44 (.50)
VAMS-Sad [0-100]	12.98 (17.31)	13.46 (8.39)	6.88 (11.60)	15.39 (6.88)

WAB-R AQ= Western Aphasia Battery-Revised Aphasia Quotient, CPIB=Communicative Participation

Information Bank, CCRSA= Communication Confidence Rating Scale for Aphasia, ALA= Assessment for Living with Aphasia, VAMS= Visual Analogue Mood Scales. There was no skewed data for these measures.

Preliminary efficacy data

Due to the feasibility design of this study, it was intentionally underpowered for definitive efficacy testing. However, clinical outcomes were analysed to investigate preliminary efficacy using ANCOVAs to ascertain differences between Immediate and Delayed groups for each outcome measure at Time 2, controlling for Time 1 (60). The results indicate that LUNA shows preliminary efficacy with 50% of measures (9/18) showing medium or large effect sizes (bolded in Table 6) for group differences at Time 2 once Time 1 was controlled for. Medium effect sizes were noted for all levels of discourse (number of narrative words, CIUs, complete and multi-clause utterances, clear reference chains), language (WAB-R AQ),

554 and psychosocial state (VAMS). Large effect sizes were noted for one discourse level - %
 555 complete and % multi-clause utterances – and were also significantly different even with
 556 low power, indicating a proportionate increase in these narrative structures.

557

558 **Table 6: Between group differences with effect sizes for each measure at T2**

		T2		
		Mean (SD)	Mean (SD)	ANCOVA F (df) p η_p^2
		Immediate	Delayed	
Narrative words:				
	number	599.29 (388.13)	506.21 (524.31)	F(1,25)=2.49, p=0.127, $\eta_p^2=0.091^*$
	percentage	69.49 (13.47)	67.28 (14.39)	F(1,25)=0.17, p=0.736, $\eta_p^2=0.005$
	per minute	45.44 (21.54)	58.27 (30.03)	F(1,25)=1.14, p=0.295, $\eta_p^2=0.044$
CIUs:				
	number	532.00 (365.92)	442.71 (471.03)	F(1,25)=3.47, p=0.074, $\eta_p^2=0.122^*$
	percentage	64.16 (13.55)	63.23 (12.89)	F(1,25)=0.42, p=0.524, $\eta_p^2=0.016$
	per minute	40.03 (20.68)	50.49 (27.33)	F(1,25)=0.55, p=0.466, $\eta_p^2=0.021$
Utterances:				
	complete	54.64 (38.71)	40.71 (43.98)	F(1,25)=2.42, p=0.132, $\eta_p^2=0.088^*$
	% complete	66.85 (22.66)	53.18 (28.87)	F(1,25)=4.91, p=0.036, $\eta_p^2=0.164^{**}$
	multiclaue	22.07 (18.74)	21.64 (26.55)	F(1,25)=2.18, p=0.152, $\eta_p^2=0.080^*$
	% multiclaue	27.55 (18.58)	25.30 (20.74)	F(1,25)=6.30, p=0.019, $\eta_p^2=0.201^{**}$
Predicate Argument Structure		1.82 (0.19)	1.69 (0.24)	F(1,25)=0.71, p=0.407, $\eta_p^2=0.028$
Story Grammar, number		4.14 (1.23)	4.07 (1.90)	F(1,25)=0.09, p=0.771, $\eta_p^2=0.003$
Reference chains, number of clear chains		13.71 (11.67)	7.85 (9.62)	F(1,25)=3.81, p=0.063, $\eta_p^2=0.137^*$
Western Aphasia Battery-Revised AQ		77.86 (12.01)	72.48 (13.3)	F(1,25)=2.38, p=0.135, $\eta_p^2=0.087^*$

Communicative Participation Information Bank	13.71 (4.00)	12.00 (5.46)	$F(1,25)=0.14, p=0.708, \eta_p^2=0.006$
Communication Confidence Rating Scale for Aphasia	29.64 (3.95)	27.50 (4.47)	$F(1,25)=1.00, p=0.328, \eta_p^2=0.038$
Assessment for Living with Aphasia	2.79 (0.55)	2.44 (0.50)	$F(1,25)=1.32, p=0.262, \eta_p^2=0.050$
Visual Analogue Mood Scales	6.89 (11.59)	15.39 (15.84)	$F(1,25)=2.52, p=0.125, \eta_p^2=0.092^*$

559 **Bold text** indicates results with moderate to large effect sizes, where **= large effect size (>0.14); *= medium
560 effect size (>0.06). Please note we have not adjusted for multiple comparisons because clinical outcomes in
561 this feasibility study are considered preliminary only.

562

563 We additionally ran a non-parametric Wilcoxon on all the measures that the ANCOVA
564 showed as having a ****large** effect size. We found that all narrative variables improve for
565 the active group, and none for the control group. For WAB and VAMS the Wilcoxon results
566 are not significant for either group (as per the ANCOVA). Note that the parametric effect
567 sizes (as shown in the table) are needed here because calculating effect size cannot be
568 reliably done for non-parametric analysis. Correlational analysis was additionally undertaken
569 to explore which factors were associated with optimum response to the LUNA treatment,
570 but there were no convincing patterns of predictors that would inform future studies or
571 practice. See S3 Correlational Analysis, for the detail.

572

573 Preliminary power calculation

574 Based on our medium WAB-R effect size of $\eta_p^2=0.08$ and above (equivalent F-effect
575 size=0.30), significant effects at $\alpha=0.05$ and 80% power=0.8 would be detected by ANCOVA
576 with a total sample size of 90 people (45 in each group; calculated using G*Power, (61).

577

578 Safety

579 Adverse Events were logged and are reported by participant. Four participants (4/28, 14%)
580 had a new health event. Two participants broke bones, one participant's health
581 deteriorated, and one participant had a further haemorrhage, a known risk factor within the
582 stroke population (62). These were unrelated to trial activity. Reports of distress were
583 recorded by session and nine episodes were recorded across the 308 sessions in the trial
584 (9/308, 3%). Episodes of distress were connected to the activities of the trial e.g., a
585 participant became upset when asked to reflect on the impact of aphasia on their lives in
586 the ALA assessment, and one episode was due to distress that the trial was finishing.
587 Episodes were managed in accordance with an established protocol, and in discussion with
588 the project manager.

589 Discussion

590 Feasibility findings are positive across all aspects of recruitment, retention, adherence,
591 missing data, treatment fidelity, and appropriateness of selected outcome measures (with
592 one exception) and collectively support a future evaluation of LUNA in a definitive trial.
593 Additionally, participants' clinical outcome findings are promising for discourse, language,
594 and psychosocial state; with particular beneficial treatment effect noted for discourse
595 production at the sentence level. These findings are considered in turn below. At 85% of
596 those eligible, recruitment in the remote LUNA trial was more than double the average
597 stroke trial (63), and other remote trials for aphasia such as the 'Big Cactus' study at 34%
598 recruitment (64) and 'TeleGain' online groups at 10% recruitment (32). The rate of
599 recruitment was exceptional at 14 participants per month. Typically, aphasia recruitment
600 rates are similar to stroke overall at 1-2 recruited per month (63-65). This finding is most

likely influenced by the pandemic, wherein it was estimated that nearly two thirds of SLT sessions were cancelled by services in the period from March-June 2020 (66), resulting in increased demand for SLT and general availability of participants with other life activities curtailed by the pandemic. Other explanations for this finding include the study being 1) largely non-restrictive inclusion criteria; 2) remotely delivered, enabling access to a wider pool of participants (supported by the wide geographical spread of resulting sample) and removing physical and transport barriers that often arise for this participant group; and 3) a *treatment* trial for chronic aphasia with waitlist-control design offering treatment to *all* participants, in the context of generally limited treatment provision for this group (67). A weakness in the recruitment was the lack of diversity in the ethnicity, education level and socioeconomic status of participants. Possible reasons for this include the remote delivery creating digital access issues.

Retention was high which, similar to the reasons for high recruitment, may have been influenced by participant interest and availability in remote treatment from the convenience of home. It is also likely influenced by 1) trial length, wherein shorter studies have higher retention (e.g., exemplified by the difference in retention at the 19 weeks (98%) and 45 week (17%) follow up points in one study (68)); 2) provider involvement wherein SLT-delivered interventions usually have higher retention than self-directed interventions (e.g., ‘TeleGain’ (32) compared to ‘Big Cactus’ (64)); and 3) supportive trial practices namely upfront scheduling, participant-sensitive scheduling (considering individuals’ timetables/constraints), and appointment reminders (69, 70) . A further motivating factor may have been working in treatment on a personally chosen narrative.

625 Adherence findings were extremely positive with 87% of treatment sessions completed as
626 scheduled, and a high proportion of participants completing most of the LUNA programme.
627 Several factors may explain these findings. Firstly, as above, supportive trial practices
628 enabled participants to attend assessment sessions at a convenient time (although for
629 treatment, regular appointment slots were scheduled). Secondly, remote delivery both
630 removes the physical barriers relating to mobility and geography that people with aphasia
631 experience and affords convenience; and participants reflected these reasons in their
632 acceptability interviews (manuscript in preparation). Thirdly, approximately half the sample
633 considered themselves 'confident' or 'very confident' in using technology, and in using
634 Zoom, on entry to the study, which may have mitigated the usual language and
635 technological challenges of Zoom. Finally, findings suggest that participants were committed
636 and motivated to complete the LUNA treatment.

637

638 Regarding participants' clinical outcomes across the WAB-R AQ, CPIB, CCRSA, ALA, and
639 VAMS-Sad, remarkably there were no missing data points, with all questions answered. Pre-
640 emptive and sustained supportive trial practices during testing points are likely to explain
641 this finding. Assessors developed a comprehensive 'assessment checklist' with a general
642 framework which was then specified for each outcome measure, pre-empting assessor and
643 participant needs in relation to the: environment (online and in participants' own homes),
644 equipment (internet, device, software, audio, visual), test material needed to complete
645 assessment, test administration (guidance for assessors on preparing, instructions, stimuli,
646 response, scoring), and evaluation (response requirements, performance). Assessors drew
647 on guidance for remote delivery, and adaptations for remote participant response e.g.,
648 annotation and remote control. Assessors employed strategies to intentionally support

participants and minimise challenge, dis-engagement, and error including (1) personalised approach (e.g., assessment packs were tailored to the device being used by each participant e.g., laptop or desktop vs iPads and Android tablets, so participants viewed guidance exactly as it appeared on their screens); (2) accessible communication, using visual supports for technology, and repetitive format to reduce cognitive demands; (3) attentiveness and flexibility e.g., monitoring fatigue and adjusting participant level of involvement required with technology where able; (4) transparency with participant and anyone in the home environment regarding privacy and assessment requirements; and (5) increased emphasis on managing distress and emotional engagement e.g., protocol for managing distress triggered by any assessment questions, and respecting participants' preferences for privacy (especially relevant to some assessment questions). Such considered effort in this trial has proved beneficial for participant engagement and resultant data quality and will be replicated in the definitive trial.

Treatment fidelity is a core consideration when planning novel treatments (71), and was established as high in this trial (39) suggesting the time investment in creating a quality and comprehensive treatment manual and provider training were effective at enabling faithful delivery of the treatment. Additionally, the structured nature of sessions and structured order to the treatment programme delivery is likely to have contributed to the positive fidelity findings. Prospective development of the fidelity checklist with involvement (72) and activity logs (71) are strengths in fidelity evaluation, that were incorporated in this trial. The fidelity data revealed some areas for future attention, including further scrutiny of missing elements in SSLT led sessions. The lowest scoring aspect of the treatment (Item 8 on the fidelity checklist) related to how both 'story' and 'non-story' targets are incorporated in

673 LUNA treatment. The manual specifies that treatment stimuli (words, sentences, story
674 components) should be chosen to include both 'story' items and 'non-story' items to
675 promote generalisation of gains beyond the treated story. 'Story' items are treatment
676 targets which will eventually be used in the treated story (i.e. story words; story sentences;
677 story macrostructure elements) and 'non-story' items are treatment targets that are not
678 intended for use in the treated story but which are related (either syntactically,
679 semantically, or structurally) to those targets that are intended to be used in the story.

680

681 Following published guidance (73), a traffic light system of progression criteria for feasibility
682 outcomes for a trial such as this was suggested as: feasible if >35% of those eligible are
683 recruited (green), with <20% not feasible (red). Retention is feasible if >85% of participants
684 are retained at follow up (green), with <65% not feasible (red). Treatment fidelity is
685 considered feasible if >75% (green), and not feasible if <50% (red). As such, remote LUNA
686 meets all the criteria proposed to progress to a definitive trial.

687

688 We acknowledge that the feasibility outcomes for this remote LUNA trial should be
689 considered cautiously with respect to evaluating LUNA in a future face-to-face trial. It is
690 encouraging that such positive findings were achieved despite the barriers of working
691 online, and against the problematic background of the pandemic. We note however that
692 retention and adherence findings are supported by eliminating participant travel and the
693 fact that so many other services were curtailed during the pandemic. More consideration of
694 supportive trial practices for this participant group is needed if delivery reverts to in person.

695

696 Blinding is an important marker of quality in trials as it reduces bias (74, 75). However, few
697 studies evaluate it or report whether it was maintained (76). Assessors were unblinded for
698 25% of participants. In some instances, it may be that this was because a rapport existed
699 with the assessor so they were potentially seen as a trusted person e.g., when a participant
700 could not access Zoom for their treatment session, they called for technological support
701 from the Assessor rather than the SLT, SSLT or Project Manager. Further consideration is
702 needed in future to avoid such instances from occurring in a definitive trial.

703

704 Although not powered to provide conclusions about clinical efficacy, effect sizes can indicate
705 where a future definitive trial may show treatment effect. LUNA's preliminary efficacy
706 findings are positive for discourse (at all three levels of language), language functioning, and
707 psychosocial state (specifically mood) with medium effect sizes; as well as demonstrating
708 treatment effect for utterance level discourse (large effect sizes, and significantly greater
709 percentages of complex and multi-clause sentences in Immediate participants' personal
710 narratives, compared to Delayed participants). Additionally, it was encouraging to see
711 preliminary efficacy for numbers of CIUs which is the most frequently reported discourse
712 indicator (13).

713

714 These findings are likely explained by the existing but limited evidence base indicating that
715 multi-level treatment provokes multi-level change (13). There is also existing evidence of a
716 relationship between discourse and overall language, where studies of other discourse
717 treatments such as scripting have also shown benefits for overall language functioning (77,
718 78). Compared to other multi-level treatments, these findings suggest that LUNA has the
719 potential to offer more comprehensive discourse outcomes. Hoover and colleagues (18)

720 describe multi-level treatment activities with 12 participants, reporting significant gains at
721 the utterance and discourse macrostructure levels but not for words; Whitworth (20)
722 reports single-case evidence for multi-level treatment producing gains across utterance and
723 discourse macrostructure levels (and, for one of the two participants, also at word level);
724 and Whitworth and colleagues (19) report within-group pre/post gains across all three levels
725 for 14 participants but, at the group level, these gains did not differ significantly from the
726 control group. The positive effect size findings from remote LUNA represent promising
727 potential for beneficial group gains at all 3 levels of language.

728

729 Although there was a medium effect size noted for the VAMS outcome measure of mood, it
730 showed ceiling effects with more than 15% of the sample scoring the maximum possible
731 score of 0 at each of the timepoints (79). Such a finding might raise concerns about content
732 validity and responsiveness suggesting reconsideration of this outcome measure for
733 inclusion in definitive trial testing. Of note is the choice of the VAMS-Sad scale, meaning that
734 mood was evaluate with a single scalar question. An outcome measure with more
735 questions, interrogating different aspects mood might be beneficial in a future trial.

736

737 There was no indication of preliminary efficacy for other measures of psychosocial state,
738 namely communication confidence, communicative participation, and aphasia-related
739 quality of life. Psychosocial state has previously been minimally measured as an outcome
740 from discourse treatment (13) and as such deserves continued attention in the future. There
741 are three possible explanations for this finding. Firstly, LUNA treatment may not be
742 sufficiently potent to improve psychosocial state. Secondly, the outcome measures may not
743 be sensitive enough, and reviewing the additional qualitative data will help guide future

outcome measures consideration. Thirdly, and most likely, the data was collected throughout the COVID-19 pandemic, through various lockdowns and release, and this context is highly likely to have affected how participants responded to questions in the psychological state measures. As such, it is not possible to make decisions about psychosocial state outcome measure selection for a future trial based on these findings.

The analysis used a novel protocol for measuring language using a person's life stories. This measure has benefits: it is based on a personal story so is likely to reflect change that is meaningful for the individuals involved; it has shown sensitivity in that several metrics from the analysis showed significant group differences following treatment and/or large effect sizes. However, there are concerns about tester burden, in that the story must be transcribed and analysed. Further developmental work could seek to find ways to make discourse analysis more efficient, and to further explore the psychometric properties of measures for personal narrative discourse.

Limitations

Some limitations are noted. Firstly, the sample recruited to this remote feasibility trial is not typical of the wider stroke and aphasia population and future studies should aim to recruit a more representative sample. With a mean age of 60 years, this sample was younger than both a national sample, a mean age of 78 years (81) and a London sample of 68.9 years (82). Additionally, both London and national samples have more ethnic diversity reporting 56% and 95.7% white participants respectively, compared to the 100% white sample in the remote LUNA study (82, 83). Secondly, measuring change in spoken discourse is a challenging undertaking, as there are numerous metrics used in the research field and their

psychometric properties are generally not well established (11, 84). To address this problem, this study employed: (1) traditional discourse metrics used in many research studies e.g., number of CIUs; (2) discourse metrics with proven psychometric properties of reliability and validity (40, 41, 84); and (3) a novel word-level metric of narrative words intended to act as a comparator for CIUs to explore the possibility that it would be more clinically feasible. Further analysis not reported here does not support the notion that the narrative words measure is a straightforward alternative to CIUs, and further research is needed with any novel measures subjected to traditional psychometric testing. Thirdly, the LUNA Discourse Analysis Protocol was created for this study and has some, not insignificant, assessor burden with analysis of each narrative at each time point taking approximately three hours. However, this represents the time for the research version of the LUNA discourse analysis protocol and the intention is to reduce this protocol in the future for clinical implementation. Finally, most of the clinical outcome measures were not validated for online delivery, except for WAB-R which has demonstrated equivalence (85), but differences in outcomes between face-to-face and online delivery of the Boston Naming Test demonstrate this cannot be assumed (86).

Future implications

This study's findings meet the set criteria for progression to definitive trial testing, in the context of remote treatment delivery. LUNA was co-designed as a face-to-face intervention but delivered online due to the COVID-19 pandemic, and the positive feasibility findings presented here are of remote LUNA. Future studies could consider a similar study of face-to-face delivery, compare face-to-face with remote delivery, or co-design a hybrid delivery model.

792

793 LUNA appears to have potential clinical value because of its multi-level language focus,
794 personalised narrative approach, and emphasis on metalinguistic and metacognitive skills
795 which translate well towards self-management during and following treatment. The original
796 co-design of LUNA with providers and recipients of SLT (22) also strengthens LUNA's
797 applicability and relevance to the treatment of people with chronic aphasia in UK clinical
798 settings. This approach serves as a good example for the development of further
799 interventions seeking to embed co-design, salience, and authentic, functional language
800 change.

801

802 **Conclusions**

803 The remote LUNA trial satisfied all feasibility progression criteria for stroke trials in trial
804 recruitment, trial retention, and treatment fidelity. High levels of participant adherence to
805 treatment sessions and completion, and low counts of missing data suggest remote LUNA is
806 acceptable. Preliminary efficacy is indicated for all three levels of discourse, and overall
807 language functioning, suggesting that it is worth exploring the clinical efficacy and cost-
808 effectiveness of LUNA in a future definitive trial.

809

810 **Acknowledgements**

811 We thank our 28 people with aphasia from across the UK for their interest and commitment
812 to LUNA. We would like to thank NHS speech and language therapists Sukhpreet Aujla,
813 Nicole Charles, Simon Grobler, and Richard Talbot, who contributed as co-designers and

advisors on LUNA, and Dr Fiona Johnson as advisor. We are grateful to the LUNA consultants with aphasia Varinder Dhaliwal, Jan Bannister, Steve Morris and Lynn Scarth who similarly contributed as advisors and co-designers. We thank our exceptional research staff: (1) assessors Lin Cockayne and Carla Magdalani, and (2) research therapists Sarah Johnston, Richard Talbot, and Gabriella Procida. Finally, we are grateful to the many City, University of London student speech and language therapists who have contributed to this study including the 12 SSLTs who delivered remote LUNA to 28 participants [Ann Mason, Anamaria Otalora-Garcia, Cemaliye Birdane, Hanka Al-Saidova, Harry Smithson, Molly Garfoot, Rosie Flynn, Rosie Sweetman, Sarah Ajrullah, Tarisa Tan, Taru Launiainen, Zain Alabbasi], the four SLT research students who evaluated treatment fidelity [Ceri Read, Katie Hall, Sarah Ajrullah, Tarisa Tan], and the 26 SSLTs who transcribed participants' personal narratives across the project lifetime [Alice Dunbar, Anamaria Otalora-Garcia, Bernadine Buckley, Bhavisha Vekhria, Daniella Stead, Eleanor Thorne, Francs James, Hannah Harvey, Harry Smithson, Janany Dayalan, Julia McGlashan, Kirsty Harris, Leema Miah, Lisanne Go, Madeleine Rowlands, Marcus Truin, Molly Garfoot, Nicola Rowland, Olivia Hogg, Rebecca Jacobs, Rosie Flynn, Sarah Ajrullah, Shannon Given, Tansy Brice, Taru Launiainen, Victor Piotto].

832 **References**

- 833 1. Donkor ES. Stroke in the 21(st) Century: A Snapshot of the Burden, Epidemiology, and
834 Quality of Life. *Stroke Res Treat*. 2018; 2018:3238165.
- 835 2. Ali M, Lyden P, Brady M, VISTA Collaboration. Aphasia and Dysarthria in Acute Stroke:
836 Recovery and Functional Outcome. *International Journal of Stroke*. 2015;10(3):400-6.
- 837 3. Berg K, Isaksen J, Wallace SJ, Cruice M, Simmons-Mackie N, Worrall L. Establishing
838 consensus on a definition of aphasia: an e-Delphi study of international aphasia researchers.
839 *Aphasiology*. 2022;36(4):385-400.
- 840 4. Kagan A. Revealing the competence of aphasic adults through conversation: A challenge
841 to health professionals. *Topics in stroke rehabilitation*. 1995;2(1):15-28.
- 842 5. Wallace SJ, Worrall L, Rose T, Le Dorze G, Cruice M, Isaksen J, Kong AP, Simmons-Mackie
843 N, Scarinci N, Gauvreau CA. Which outcomes are most important to people with aphasia and
844 their families? An international nominal group technique study framed within the ICF.
845 *Disability and rehabilitation*. 2017 Jul 3;39(14):1364-79.
- 846 6. Schiffrin D, Tannen D, Hamilton H,E. Introduction to the First Edition. In: *The Handbook of*
847 *Discourse Analysis*. 2015. p. 1-7.
- 848 7. Labov W. Some further steps in narrative analysis. *Journal of Narrative & Life History*.
849 1997;7(1-4):395-415.

- 850 8. Brady MC, Kelly H, Godwin J, Enderby P, Campbell P. Speech and language therapy for
851 aphasia following stroke. The Cochrane database of systematic reviews. 2016(6):CD000425.
- 852 9. Hebert D, Lindsay MP, McIntyre A, Kirton A, Rumney PG, Bagg S, et al. Canadian stroke
853 best practice recommendations: Stroke rehabilitation practice guidelines, update 2015. Int J
854 Stroke. 2016;11(4):459-84.
- 855 10. Stark BC, Dutta M, Murray LL, Fromm D, Bryant L, Harmon TG, et al. Spoken Discourse
856 Assessment and Analysis in Aphasia: An International Survey of Current Practices. J Speech
857 Lang Hear Res. 2021;64(11):4366-89.
- 858 11. Bryant L, Spencer E, Ferguson A. Clinical use of linguistic discourse analysis for the
859 assessment of language in aphasia. Aphasiology. 2017;31(10):1105-26.
- 860 12. Wallace SJ, Worrall L, Rose T, Le Dorze G, Breitenstein C, Hilari K, et al. A core outcome
861 set for aphasia treatment research: The ROMA consensus statement. Int J Stroke.
862 2019;14(2):180-5.
- 863 13. Dipper L, Marshall J, Boyle M, Botting N, Hersh D, Pritchard M, et al. Treatment for
864 improving discourse in aphasia: a systematic review and synthesis of the evidence base.
865 Aphasiology. 2021;35(9):1125-67.
- 866 14. Bryant L, Ferguson A, Spencer E. Linguistic analysis of discourse in aphasia: A review of
867 the literature. Clinical linguistics & phonetics. 2016;30(7):489-518.
- 868 15. Cruice M, Botting N, Marshall J, Boyle M, Hersh D, Pritchard M, et al. UK speech and
869 language therapists' views and reported practices of discourse analysis in aphasia

870 rehabilitation. International journal of language & communication disorders.
871 2020;55(3):417-42.

872 16. Sze WP, Hameau S, Warren J, Best W. Identifying the components of a successful spoken
873 naming therapy: a meta-analysis of word-finding interventions for adults with aphasia.
874 Aphasiology. 2020:1-40.

875 17. Poirier S, Fossard M, Monetta L. The efficacy of treatments for sentence production
876 deficits in aphasia: a systematic review. Aphasiology. 2023;37(1):122-42.

877 18. Hoover EL, Caplan D, Waters G, Budson A. Effects of impairment-based individual and
878 socially oriented group therapies on verb production in aphasia. Aphasiology.
879 2015;29(7):781-98.

880 19. Whitworth A, Leitão S, Cartwright J, Webster J, Hankey GJ, Zach J, et al. NARNIA: a new
881 twist to an old tale. A pilot RCT to evaluate a multilevel approach to improving discourse in
882 aphasia. Aphasiology. 2015;29(11):1345-82.

883 20. Whitworth, A. Using narrative as a bridge: Linking language processing models with real-
884 life communication. In Seminars in speech and language. 2010; 31 (1): 064-075.

885 21. Dipper L, Marshall J, Boyle M, Hersh D, Botting N, Cruice M. Creating a theoretical
886 framework to underpin discourse assessment and intervention in aphasia. Brain Sci.
887 2021;11(2):1-18.

- 888 22. Cruice M, Aujla S, Bannister J, Botting N, Boyle M, Charles N, et al. Creating a novel
889 approach to discourse treatment through coproduction with people with aphasia and
890 speech and language therapists. *Aphasiology*. 2022;36(10), 1159-1181.
- 891 23. Cherney LR, Kaye RC, Lee JB, van Vuuren S. Impact of Personal Relevance on Acquisition
892 and Generalization of Script Training for Aphasia: A Preliminary Analysis. *American journal*
893 *of speech-language pathology*. 2015;24(4):S913-22.
- 894 24. Kiran S, Thompson CK. Neuroplasticity of Language Networks in Aphasia: Advances,
895 Updates, and Future Challenges. *Frontiers in neurology*. 2019;10:295.
- 896 25. Corsten S, Schimpf EJ, Konradi J, Keilmann A, Hardering F. The participants' perspective:
897 how biographic–narrative intervention influences identity negotiation and quality of life in
898 aphasia. *International journal of language & communication disorders*. 2015;50(6):788-800.
- 899 26. Olness GS, Ulatowska HK. Personal narratives in aphasia: Coherence in the context of
900 use. *Aphasiology*. 2011;25(11):1393-413.
- 901 27. Strong KA, Shadden BB. The Power of Story in Identity Renegotiation: Clinical
902 Approaches to Supporting Persons Living With Aphasia. *Perspectives of the ASHA special*
903 *interest groups*. 2020;5(2):371-83.
- 904 28. Wadams A, Suting L, Lindsey A, Mozeiko J. Metacognitive Treatment in Acquired Brain
905 Injury and Its Applicability to Aphasia: A Systematic Review. *Frontiers in Rehabilitation*
906 *Sciences*. 2022;3.

907 29. Hernández-Sacristán C, Rosell-Clari V, Serra-Alegre E, Quiles-Climent J. On natural
908 metalinguistic abilities in aphasia: A preliminary study. *Aphasiology*. 2012;26(2):199-219.

909 30. Hall N, Boisvert M, Steele R. Telepractice in the assessment and treatment of individuals
910 with aphasia: a systematic review. *Int J Telerehabil*. 2013;5(1):27-38.

911 31. Woolf C, Cauté A, Haigh Z, Galliers J, Wilson S, Kessie A, et al. A comparison of remote
912 therapy, face to face therapy and an attention control intervention for people with aphasia:
913 a quasi-randomised controlled feasibility study. *Clin Rehabil*. 2016;30(4):359-73.

914 32. Pitt R, Theodoros D, Hill AJ, Russell T. The development and feasibility of an online
915 aphasia group intervention and networking program - TeleGAIN. *Int J Speech Lang Pathol*.
916 2019 Feb;21(1):23-36.

917 33. Carragher M, Steel G, Talbot R, Devane N, Rose ML, Marshall J. Adapting therapy for a
918 new world: storytelling therapy in EVA Park. *Aphasiology*. 2021;35(5):704-729

919 34. Billingham SAM, Whitehead AL, Julious SA. An audit of sample sizes for pilot and
920 feasibility trials being undertaken in the United Kingdom registered in the United Kingdom
921 Clinical Research Network database. *BMC Med Res Methodol*. 2013;13:104-.

922 35. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. *Pharmaceutical*
923 *Statistics*. 2005;4(4):287-91.

924 36. Enderby PM, Wood VA, Wade DT, Hower RL. The Frenchay Aphasia Screening Test: a
925 short, simple test for aphasia appropriate for non-specialists. *Int Rehabil Med*.
926 1987;8(4):166-70.

927 37. Rose TA, Worrall LE, Hickson LM, Hoffmann TC. Guiding principles for printed education
928 materials: Design preferences of people with aphasia. *International Journal of Speech-*
929 *Language Pathology*. 2012;14(1):11-23.

930 38. Borrelli B. The Assessment, Monitoring, and Enhancement of Treatment Fidelity In Public
931 Health Clinical Trials. *J Public Health Dent*. 2011;71(s1):S52-63.

932 39. Heilemann C, Best W, Johnson F, Beckley F, Edwards S, Maxim J, et al. Investigating
933 treatment fidelity in a conversation-based aphasia therapy. *Aphasie und verwandte*
934 *Gebiete/Aphasie et domaines associés*. 2014;37(2):14-26.

935 40. Pritchard M, Hilari K, Cocks N, Dipper L. Psychometric properties of discourse measures
936 in aphasia: acceptability, reliability, and validity. 2018;53(6):1078-1093

937 41. Boyle M. Test-Retest Stability of Word Retrieval in Aphasic Discourse. *JOURNAL OF*
938 *SPEECH LANGUAGE AND HEARING RESEARCH*. 2014;57(3):966-78.

939 42. Kertesz A. *The Western Aphasia Battery–Revised (WAB-R)*. Pearson; 2007.

940 43. Kertesz A, Poole E. *The Aphasia Quotient: The Taxonomic Approach to Measurement of*
941 *Aphasic Disability*. *Canadian Journal of Neurological Sciences*. 1974;1(1):7-16.

942 44. Bond B. *The test-retest reliability of the Western Aphasia Battery-Revised [MA thesis]*.
943 University of Kansas; 2019.

944 45. Dekhtyar M, Braun E, J., Billot A, Foo L, Kiran S. Videoconference Administration of the
945 Western Aphasia Battery–Revised: Feasibility and Validity. *American Journal of Speech-*
946 *Language Pathology*. 2020;29(2):673-87.

947 46. Baylor C, Yorkston K, Eadie T, Kim J, Chung H, Amtmann D. The Communicative
948 Participation Item Bank (CPIB): item bank calibration and development of a disorder-generic
949 short form. *J Speech Lang Hear Res.* 2013;56(4):1190-208.

950 47. Baylor C, Oelke M, Bamer A, Hunsaker E, Off C, Wallace SE, et al. Validating the
951 Communicative Participation Item Bank (CPIB) for use with people with aphasia: an analysis
952 of differential item function (DIF). *Aphasiology.* 2017;31(8):861-78.

953 48. Cherney LR, Babbitt EM, Semik P, Heinemann AW. Psychometric Properties of the
954 Communication Confidence Rating Scale for Aphasia (CCRSA): Phase 1. *Aphasiology.*
955 2011;18(4):352-60.

956 49. Babbitt EM, Heinemann AW, Semik P, Cherney LR. Psychometric properties of the
957 Communication Confidence Rating Scale for Aphasia (CCRSA): Phase 2. *Aphasiology.*
958 2011;25(6-7):727-35.

959 50. Kagan A, Simmons-Mackie N, Victor JC, Carling-Rowland A, Hoch J, Huijbregts M.
960 Assessment for Living With Aphasia (ALA). APA PsycTests.2013.

961 51. Simmons-Mackie N, Kagan A, Victor JC, Carling-Rowland A, Mok A, Hoch JS, et al. The
962 assessment for living with aphasia: reliability and construct validity. *Int J Speech Lang Pathol.*
963 2014;16(1):82-94.

964 52. Stern RA, Arruda JE, Hooper CR, Wolfner GD, Morey CE. Visual analogue mood scales to
965 measure internal mood state in neurologically impaired patients: Description and initial
966 validity evidence. *Aphasiology.* 1997;11(1):59-71.

967 53. Marshall J, Cauté A, Chadd K, Cruice M, Monnelly K, Wilson S, et al. Technology-
968 enhanced writing therapy for people with aphasia: results of a quasi-randomized waitlist
969 controlled study. *International Journal of Language & Communication Disorders*.
970 2019;54(2):203-20.

971 54. Thomas SA, Walker MF, Macniven JA, Haworth H, Lincoln NB. Communication and Low
972 Mood (CALM): a randomized controlled trial of behavioural therapy for stroke patients with
973 aphasia. *Clin Rehabil*. 2013;27(5):398-408.

974 55. Barrows PD, Thomas SA. Assessment of mood in aphasia following stroke: validation of
975 the Dynamic Visual Analogue Mood Scales (D-VAMS). *Clin Rehabil*. 2018;32(1):94-102.

976 56. Nyenhuis DL, Yamamoto C, Stern RA, Luchetta T, Arruda JE. Standardization and
977 validation of the visual analog mood scales. *Clin Neuropsychol*. 1997;11(4):407-15.

978 57. House ED, Arruda JE, Andrasik F, Grazzi L. The Reliability and Validity of the Visual Analog
979 Mood Scales in Non-English-Speaking Pain Patients. *Pain practice*. 2012;12(8):626-32.

980 58. Perepletchikova F, Kazdin AE. Treatment Integrity and Therapeutic Change: Issues and
981 Research Recommendations. *Clinical Psychology: Science and Practice*. 2005;12(4):365-83.

982 59. Standard Occupational Classification [Internet].; 2020 [cited 29.03.23]. Available from:
983 [https://www.ons.gov.uk/methodology/classificationsandstandards/standardoccupationalcla](https://www.ons.gov.uk/methodology/classificationsandstandards/standardoccupationalclassificationsoc/soc2020/soc2020volume2codingrulesandconventions)
984 [ssificationsoc/soc2020/soc2020volume2codingrulesandconventions](https://www.ons.gov.uk/methodology/classificationsandstandards/standardoccupationalclassificationsoc/soc2020/soc2020volume2codingrulesandconventions).

985 60. Marshall J, Devane N, Talbot R, Cauter A, Cruice M, Hilari K, et al. A randomised trial of
986 social support group intervention for people with aphasia: A Novel application of virtual
987 reality.(Research Article). PloS one. 2020;15(9):e0239715.

988 61. Faul F, Erdfelder E, Lang A, Buchner A. G*Power 3: a flexible statistical power analysis
989 program for the social, behavioral, and biomedical sciences. Behav Res Methods.
990 2007;39(2):175-91.

991 62. Elkind MSV. Outcomes After Stroke: Risk of Recurrent Ischemic Stroke and Other Events.
992 Am J Med. 2009;122(4, Supplement 2):S7-S13.

993 63. McGill K, Sackley CM, Godwin J, McGarry J, Brady MC. A systematic review of the
994 efficiency of recruitment to stroke rehabilitation randomised controlled trials. Trials.
995 2020;21(1):68.

996 64. Palmer R, Enderby P, Cooper C, Latimer N, Julious S, Paterson G, et al. Computer therapy
997 compared with usual care for people with long-standing aphasia poststroke: a pilot
998 randomized controlled trial. Stroke. 2012;43(7):1904-11.

999 65. Northcott S, Thomas S, James K, Simpson A, Hirani S, Barnard R, et al. Solution Focused
1000 Brief Therapy in Post-Stroke Aphasia (SOFIA): feasibility and acceptability results of a
1001 feasibility randomised wait-list controlled trial. BMJ Open. 2021;11(8):e050308.

1002 66. Clegg J, O'Flynn P, Just P. Speech and language therapy during and beyond COVID-19:
1003 building back better with people who have communication and swallowing needs. Royal
1004 College of Speech and Language Therapy; 2021.

1005 67. Palmer R, Witts H, Chater T. What speech and language therapy do community dwelling
1006 stroke survivors with aphasia receive in the UK? PLoS One. 2018;13(7):e0200096.

1007 68. Efstratiadou EA, Papathanasiou I, Holland R, Varlokosta S, Hilari K. Efficacy of Elaborated
1008 Semantic Features Analysis in Aphasia: a quasi-randomised controlled trial. Aphasiology.
1009 2019;33:12, 1482-1503.

1010 69. Spell LA, Richardson JD, Basilakos A, Stark BC, Teklehaimanot A, Hillis AE, et al.
1011 Developing, Implementing, and Improving Assessment and Treatment Fidelity in Clinical
1012 Aphasia Research. Am J Speech Lang Pathol. 2020;29(1):286-98.

1013 70. Page SJ, Persch AC. Recruitment, retention, and blinding in clinical trials. Am J Occup
1014 Ther. 2013;67(2):154-61.

1015 71. Behn N, Harrison M, Brady MC, Breitenstein C, Carragher M, Fridriksson J, et al.
1016 Developing, monitoring, and reporting of fidelity in aphasia trials: core recommendations
1017 from the collaboration of aphasia trialists (CATs) trials for aphasia panel. Aphasiology.
1018 2022:1-23.

1019 72. Brogan E, Ciccone N, Godecke E. Treatment fidelity in aphasia randomised controlled
1020 trials. Aphasiology. 2019;33(7):759-79.

1021 73. Lewis M, Bromley K, Sutton CJ, McCray G, Myers HL, Lancaster GA. Determining sample
1022 size for progression criteria for pragmatic pilot RCTs: the hypothesis test strikes back! Pilot
1023 and Feasibility Studies. 2021;7(1):40.

1024 74. M Delgado-Rodríguez, J Llorca. Bias. J Epidemiol Community Health. 2004;58(8):635-41.

1025 75. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing
1026 the quality of reports of randomized clinical trials: Is blinding necessary? *Control Clin Trials*.
1027 1996;17(1):1-12.

1028 76. Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. *Control Clin Trials*.
1029 2004;25(2):143-56.

1030 77. Cherney LR. Oral Reading for Language in Aphasia (ORLA): Evaluating the Efficacy of
1031 Computer-Delivered Therapy in Chronic Nonfluent Aphasia. *Topics in Stroke Rehabilitation*.
1032 2010;17(6):423-31.

1033 78. Cherney LR, Lee JB, Kim KA, van Vuuren S. Web-based Oral Reading for Language in
1034 Aphasia (Web ORLA®): A pilot randomized control trial. *Clin Rehabil*. 2021;35(7):976-87.

1035 79. Terwee CB, Bot SDM, de Boer MR, van der Windt, Daniëlle A. W. M., Knol DL, Dekker J,
1036 et al. Quality criteria were proposed for measurement properties of health status
1037 questionnaires. *J Clin Epidemiol*. 2007;60(1):34-42.

1038 80. Hickin J, Mehta B, Dipper L. To the sentence and beyond: a single case therapy report for
1039 mild aphasia. *Aphasiology*. 2015;29(9):1038-61.

1040 81. Mitchell C, Gittins M, Tyson S, Vail A, Conroy P, Paley L, et al. Prevalence of aphasia and
1041 dysarthria among inpatient stroke survivors: describing the population, therapy provision
1042 and outcomes on discharge. *Aphasiology*. 2021;35(7):950-60.

1043 82. Clery A, Bhalla A, Rudd AG, Wolfe CDA, Wang Y. Trends in prevalence of acute stroke
1044 impairments: A population-based cohort study using the South London Stroke Register. PLoS
1045 Med. 2020;17(10):e1003366.

1046 83. Suhail IS, Forbes H, Mathur R, Smeeth L, Pearce N, Warren-Gash C. Ethnicity and risk of
1047 diagnosed dementia after stroke: a cohort study using the Clinical Practice Research
1048 Datalink. J Epidemiol Community Health. 2020;74(2):114.


1049 84. Pritchard M, Hilari K, Cocks N, Dipper L. Reviewing the quality of discourse information
1050 measures in aphasia. International Journal of Language & Communication Disorders.
1051 2017;52(6):689-732.

1052 85. Dekhtyar M, Braun EJ, Billot A, Foo L, Kiran S. Videoconference Administration of the
1053 Western Aphasia Battery-Revised: Feasibility and Validity. Am J Speech Lang Pathol. 2020
1054 May 8;29(2):673-87.

1055 86. Brearly TW, Shura RD, Martindale SL, Lazowski RA, Luxton DD, Shenal BV, et al.
1056 Neuropsychological Test Administration by Videoconference: A Systematic Review and
1057 Meta-Analysis. Neuropsychol Rev. 2017;27(2):174-86.


1058 **Supporting information**

1059 **S1 Checklist. LUNA Template for Intervention Description and Replication (TIDieR)**
1060 **S2 Appendix. LUNA Discourse Metrics**
1061 **S3 Correlational Analysis. Additional correlational analysis for the LUNA clinical outcome**
1062 **measures**
1063 **S4 Dataset. LUNA Dataset**
1064 **S5 Checklist. CONSORT 2010 checklist of information to include when reporting a pilot or**
1065 **feasibility trial.**











[Click here to access/download](#)

Supporting Information
S3 Correlational Analysis.docx









[Click here to access/download](#)

Other

LUNA Protocol.docx





[Click here to access/download](#)

Other

[Ethics_application_ETH1920-
1651_\(amendments\)_Decision.pdf](#)

